Intellia: Intellia Focuses on Pipeline Development Amid Stiff Competition
Studies on NTLA's gene-edited therapy, nex-z, are progressing well while other pipelines are picking up pace. Stiff competition in the target market is a woe.
Read full article »
Intellia Therapeutics is a Massachusetts-based biotechnology company that researches and develops genome editing therapies to treat genetic and oncological diseases.
Read more